Abstract. The soluble urokinase-type plasminogen activator receptor (suPAR) and the urokinase-type plasminogen activator receptor (uPAR) have been proposed as useful biomarkers of tumor progression. Recently, suPAR was associated with chemoresistance in lung cancer. However, its clinical significance in leukemia has not previously been investigated. The present study examined the plasma levels of suPAR and the expression of the uPAR on bone marrow (BM) cells in 86 patients with leukemia at diagnosis prior to chemotherapy and 26 normal subjects (control group). The plasma suPAR levels were measured using ELISA, whilst uPAR expression was assayed by flow cytometry analysis. In addition, cell surface uPAR expression on K562 and multidrug-resistant K562/ADM cell lines was studied by western blotting. On admission and follow-up, the levels of suPAR in patients with leukemia were significantly increased compared with controls. Systemic levels of suPAR were strongly associated with the numbers of white blood cells. A case was defined as uPAR-positive (uPAR + ) if >20% of the gated cells expressed uPAR. In comparison with 26 healthy BM samples that were negative for uPAR expression, 48 (55.8%) of the 86 leukemia patients were uPAR +
Introduction
Urokinase plasminogen activator receptor (uPAR) is a receptor which is mainly expressed on various immunologically-active cells including macrophages, neutrophils, activated T lymphocytes and as endothelial cells. uPAR performs an important role in plasminogen activation, cell adhesion and migration-all central aspects of inflammatory processes, and numerous disease prognoses (1) . suPAR, the soluble form of uPAR, has emerged as a valuable indicator of the activation state of the immune system. suPAR is detectable in low, but constant concentrations in the plasma of healthy individuals (2, 3) . Increased suPAR levels have been observed in numerous pathological conditions including infection (4-6), autoimmune diseases (7, 8) and neoplastic diseases (9) , as well as during pregnancy (10) and pregnancy-associated disorders (11, 12) . Preliminary studies indicate that increased plasma suPAR concentrations were observed in patients with non-small-cell lung (13) , advanced breast and colorectal (14) and ovarian cancer (15) . In ovarian cancer, high preoperative levels of suPAR were associated with a decreased survival rate (15) . The association between increased plasma suPAR and increased mortality has also been documented in patients with HIV (16) and sepsis (17) . suPAR is considered to be a marker of disease severity and risk of mortality in a heterogeneous cohort of patients with a variety of diseases (18) (19) (20) . The independent prediction of clinical outcome by suPAR suggests it could be of value in prognostic algorithms (20) .
Mustjoki et al (21) first reported the plasma soluble urokinase receptor in acute leukemia patients in 1999, and the results suggested that cell surface uPAR may also be a useful marker for leukemia subclassification, and that high level of plasma suPAR were associated with resistance to chemotherapy in acute myeloid leukemia (AML). However, a clinical study by Graf et al (22) suggested that cases with increased proportions of uPAR-positive (uPAR + ) cells were characterized by a significantly lower remission rate to AML-cooperative group therapy and an increased risk for relapse. Evaluation of leukemic relapse is difficult and thus early clinical intervention is often delayed. The prognostic value of plasminogen activation in patients with leukemia has been difficult to assess as there have been few studies on leukemia patients and those reported studies used small Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia cohort of patients. To overcome these weaknesses, the present study analyzed both cell surface and plasma compartments of blood samples from patients with leukemia, investigated the association between markers of plasminogen activation and the treatment response. Western blotting. To analyze protein expression in the cells and culture supernatants, cells were cultured for 48 h. For cellular membrane proteins, the cells were washed with ice cold PBS and then extracted with lysis buffer at 4˚C (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% sodium dodecyl sulfate, 0.5% deoxycholic acid, 0.02% sodium azide, 1% NP-40, 2.0 mg/ml aprotinin and 1 mM phenylmethylsulfonyl fluoride) supplemented with Complete Protease Inhibitor Cocktail tablets (Roche Diagnostics, Tokyo, Japan). Following storage on ice for 30 min at 4˚C, the lysates were centrifuged at 20,000 x g for 30 min at 4˚C and the supernatants (soluble proteins) were collected. The protein concentration was measured using Pierce 660 nm Protein Assay (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Subsequent to each sample being mixed 1:1 with 5X Laemmli sample buffer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and boiled for 5 min, 20 µg of protein were separated using 7% SDS-PAGE. The proteins were transferred to polyvinylidene fluoride membranes (ATTO Corporation, Tokyo, Japan) by electroblotting, blocked with TBS (pH 7.4) with 0.05% Tween-20, and supplemented with 0.3% non-fat dry milk for 1 h at room temperature (RT). The membranes were next incubated overnight at 4˚C with primary antibodies against uPAR [no. 17-3979; dilution, 1:1,000 in TBST (TBS-Tween-20)]. Following extensive washing with TBST, the membranes were incubated for 1 h at RT with peroxidase-conjugated anti-mouse secondary antibodies (no. A7851; dilution, 1:100,000 in TBST Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). β-actin was used as the internal control. The signals were visualized using an LAS-3000 Image Analyzer (Fujifilm, Tokyo, Japan) subsequent to the membranes being incubated with the ECL Prime Western Blotting Detection reagent (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) for 5 min at room temperature.
Materials and methods

Study
RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted with TRIzol reagent supplied by Sigma-Aldrich (Merck KGaA; no. T9424) according to the manufacturer's protocol, then the RNA was removed using RNases supplied by Sigma-Aldrich (Merck KGaA; no. R6513) and reverse transcribed using a SuperScript III First-strand synthesis system (Invitrogen; Thermo Fisher Scientific, Inc.) to generate cDNA according to the manufacturer's protocol. PCR was performed using a LightCycler 480 SYBR-Green I Master (Roche Diagnostics, West Sussex, UK) according to the manufacturer's protocol. Transcription of β-actin was examined with the primers 5'-TGG CAC CCA GCA CAA TGAA-3' and 5'-CTA AGT CAT AGT CCG CCT AGA AGCA-3. Primers for uPAR were 5'-AAC AGT GCC TGG ATG TGG TG-3' and 5'-GAA GTG GAA GGT GTC GTT GTTG-3'. Subsequent to the initial denaturation step of 5 min at 95˚C, 40 cycles of amplification for each primer pair were carried out. Each cycle consisted of: Denaturation, 10 sec at 95˚C; annealing, 20 sec at 60˚C; and elongation, 10 sec at 72˚C. Final elongation temperature was 65˚C for 1 min. Relative levels of gene expression was measured using a LightCycler 480 (Roche Diagnostics) according to the manufacturer's protocol. The relative changes in the expression levels of uPAR genes were normalized using the 2 -ΔΔCq method against the level of β-actin gene expression in each sample. Experiments were carried out at least in duplicate for each data point (23) .
Statistical analysis.
A descriptive statistical analysis was performed for all biological variables. Data obtained to measure the normal distribution were analyzed using the Kolmogorov-Smirnov test. Data in conformity with normal distribution were analyzed using the Student's t-test and those not conforming to normal distribution were analyzed using the Mann-Whitney U test. Results obtained by measurements are presented as the mean ± standard deviation. The area beneath the receiver operating characteristics (ROC) curve was used to calculate the discriminative ability of suPAR to determine patients following chemotherapy. Sensitivity, specificity, negative predictive values, and positive predictive values were calculated for these markers on the basis of ROC curves. P<0.05 was considered to indicate a statistically significant difference.
Results
Baseline data. Within the enrollment period, 86 patients were included in the present study. The patients' baseline characteristics are summarized in Table I . The subjects comprised of 66.3% men, and the median age was 43.8 years. Acute leukemia was subsequently diagnosed in 76 of these patients: 51 subjects had AML (FAB classes, M1: 5; M2: 7; M3: 9; M4: 13; M5: 12; and M6: 5); and 25 subjects had acute lymphocytic leukemia (ALL). A total of 6 subjects had chronic myeloid leukemia (CML) and 4 subjects had chronic lymphocytic leukemia (CLL). The diagnoses were based on morphological, cytochemical, cytogenetic and cell surface marker expression. Blood samples from 26 healthy volunteers were used as controls. The median suPAR level was 3.38 ng/ml (range, 1.89 to 8.32 ng/ml) in patients with leukemia. In control subjects the median suPAR level was 2.76 ng/ml (range, 1.63 to 2.91 ng/ml), which was statistically significant compared with patients with leukemia (P<0.05). There was no association between sex and plasma suPAR concentration (P>0.05) in patients with leukemia. The median uPAR expression rate was 36.2% in patients with leukemia, and 18% was observed in healthy adults.
Subtypes of leukemia exhibit different suPAR levels.
Plasma levels of suPAR were elevated in patients with leukemia compared with healthy subjects. In all subtypes of leukemia, the suPAR value was increased compared with chronic leukemia patients (3.53±1.15 vs. 2.27±0.36 ng/ml; P<0.05) and suPAR values of AML were increased compared with ALL (3.93±1.16 vs. 2.69±0.53 ng/ml; P<0.05). Patients with AML had significantly increased plasma levels of suPAR compared with other group leukemia patients, 2.44±0.31 ng/ml in CML (P<0.05); 2.02±0.11 ng/ml in CLL (P<0.05; Fig. 1) .
In all subtypes of the 51 patients with AML, suPAR values were measured as follows: M1 (n=5, 2.62±0.34 ng/ml); M2 (n=7, 3.65±0.88 ng/ml); M3 (n=9, 5.11±1.45 ng/ml); M4 (n=13, 3.64±0.65 ng/ml); M5 (n=12, 4.58±0.74 ng/ml); and M6 (n=5, 2.78±0.2 ng/ml). As shown in Fig. 2 , the levels of suPAR in M3 and M5 were increased compared with other subtype groups (P<0.005).
The present study additionally subdivided the patients based on age using 10-year intervals and assessed suPAR levels in different age groups. As shown in Fig. 3 , suPAR levels in patients <20 years old were reduced compared with older patients. There was no association between other age groups and plasma suPAR concentration (P>0.05). Analysis of suPAR levels using the ROC revealed the area under the curve to be 0.871 (Fig. 4 ).
Differentiated type leukemia shows different uPAR expression.
The present study assessed cellular uPAR expression-if the percentage of positive events was >20%, the sample was (Fig. 5) .
Correlations of uPAR and suPAR with leukemia clinical parameters.
Patients were divided into two groups according to the suPAR expression level (> vs. <; mean value, 3.38 ng/ml). The difference between these groups was calculated with the χ 2 test. The good response group was defined as those demonstrating complete remission with 1-2 cycles of chemotherapy and no relapse within five months; and the poor response group was those having residual disease subsequent to ≥2 cycles of chemotherapy, patient mortality or relapse during therapy (within five months). As demonstrated in Table II , the treatment response of the uPAR and suPAR co-expression group 
Patients Positive Negative P-value Positive Negative P-value Co-positive Co-negative P-value (Fig. 6 ).
RT-qPCR mRNA analysis additionally confirmed these results.
Discussion
The present study investigated whether plasma level of suPAR or cell surface expression uPAR was associated with leukemia pathogenesis and treatment response. The results demonstrated that suPAR was significantly elevated in the plasma of patients with acute myeloid leukemia. However, uPAR was identified on the surface of leukemic blasts in both myeloid and lymphoid leukemia patients. Secondly, high levels of suPAR and positive surface uPAR expression were associated with decreased chemosensitivity in the leukemic cells. Thirdly, uPAR expression level on multidrug-resistant K562/ADM cell surface was increased compared with that on the sensitive K562 cell surface. Previous studies have demonstrated that suPAR was associated with cancer development, and was also an important biomarker reflecting disease severity, and mortality in a variety of diseases (24) (25) (26) . Kaya et al revealed that suPAR was an important and sensitive biomarker that could predict infection status in an early stage of febrile neutropenia, and for patients with hematologic malignancies (27) . The results of the present study demonstrated that high levels of suPAR were associated with decreased chemosensitivity in leukemic cells and patients.
uPAR is expressed in differentiated myeloid cells, but not in cells exhibiting lymphoid markers (18) . The immature hematopoietic cells, including cluster of differentiation (CD) 34 + progenitor cells, and less differentiated bone marrow cells do not express uPAR (18) . In the bone marrow, uPAR has been identified in mature monocytes, however not in red blood cells, erythroblasts or platelets (28 (21) . In small-cell lung cancer cell lines, uPAR + cells were more resistant to chemotherapeutic drug treatment compared with uPAR -cells (24) . Indeed, the present study observed lower uPAR expression on K562 cells and increased expression in multidrug-resistant K562/ADM cells. Gutova et al (24) investigated the role of uPAR and the multi-drug resistance gene in several types of human cancer. Whether uPAR overexpression is responsible for leukemia multidrug resistance still requires additional investigation. Future studies will need to additionally evaluate the effect and mechanism of uPAR + expression in correlation with treatment resistance in patients with leukemia, particularly whether the downregulation of uPAR expression would influence MDR1 expression to ameliorate chemosensitivity or improve treatment response.
In summary, the present study revealed that the level of plasma suPAR represents a useful marker for leukemia subclassification. Plasma suPAR and/or cell surface uPAR expression associates with chemotherapy resistance in patients with leukemia.
